Our top pick for
Building a portfolio
Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$1.45 - USD$5.5|
|50-day moving average||USD$3.7549|
|200-day moving average||USD$3.3924|
|Wall St. target price||USD$8.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.352|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$108.6 million|
|Gross profit TTM||USD$47.6 million|
|Return on assets TTM||-14.04%|
|Return on equity TTM||-67.72%|
|Market capitalisation||USD$605.6 million|
TTM: trailing 12 months
There are currently 22.0 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 30.6% up from 16.9 million last month.
There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.
Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 3.2 million). Rigel Pharmaceuticals's SIR currently stands at 6.98. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 6980 shares are currently held short.
However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1684% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 168 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Rigel Pharmaceuticals.
Find out more about how you can short Rigel Pharmaceuticals stock.
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Rigel Pharmaceuticals's shares were split on a 1:9 basis on 24 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $1.45 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.4721. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co. , Ltd.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.